Contraindicated (1)bortezomib will enhance the amount or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or average CYP2C19 inhibitors may boost mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction. The sq. root of two would be the frequency ratio of the tritone https://glennz542rhr1.bloguerosa.com/profile